LAG3 and neoplasm: ORR was at least 3.5-fold higher in patients with LAG-3 expression in at least 1% of tumour-associated immune cells within the tumor margin (n = 33) than that in the patients with less than 1% LAG-3 expression (n = 22) (18% and 5%, respectively) (Ascierto et al. 2017).